
FIG. 1


Primary Endpoint
73%
54%
27%
2 week
4 week
12 week
Percentage Achieved
80
70
60
50
40
30
20
10
0



CDA
CDA with No CS
73
54
12
27
Day 15
Day 29
Day 85
Study Days
Response Rate (%)
100
80
60
40
20
0

FIG. 2



CR Achieved, %
100%
80%
60%
40%
20%
0%
17%
25%
n=121
n=121
12 Weeks
24 Weeks
(12 wk
Off Treatment)

FIG. 3

FIG. 4



PRN1008 Treatment
Post Treatment Follow Up
Median (IQR) PDAI Score
25
20
15
10
5
0
N =
26
26
24
24
24
24
24
24
Days
1
29
57
85
113
141
169

FIG. 5



PRN1008 Treatment
Post Treatment Follow Up
Mean ± 95% CI PDAI Score
0
5
10
15
20
25
N =
26
26
24
24
24
24
24
24
Days
1
29
57
85
113
141
169

FIG. 6



Primary Endpoint
Percentage Achieved
80
70
60
50
40
30
20
10
0
29%
43%
50%
n=4/14
n=6/14
n=7/14
2 week
4 week
12 week

FIG. 7



Primary Endpoint
80%
n=12/15
12 week
53%
n=8/15
4 week
27%
n=4/15
2 week
Percentage Achieved
0
10
20
30
40
50
60
70
80

FIG. 8A



CDA Achieved, %
100%
80%
60%
40%
20%
0%
60%
87%
n=9/15
n=13/15
4 Weeks Primary Endpoint
12 Weeks

FIG. 8B



CDA Achieved, %
100%
80%
60%
40%
20%
0%
50%
50%
n=7/14
n=7/14
4 Weeks Primary Endpoint
12 Weeks

FIG. 9A



CR Achieved, %
100%
80%
60%
40%
20%
0%
13%
33%
40%
n=2/15
n=5/15
n=6/15
12 Weeks
24 Weeks
28 Weeks
(4 wk
Off Treatment)

FIG. 9B



CR Achieved, %
100%
80%
60%
40%
20%
0%
7%
7%
7%
n=1/14
n=1/14
n=1/14
12 Weeks
24 Weeks
28 Weeks
(4 wk
Off Treatment)

FIG. 10




PDAI Activity Score
0
2
4
6
8
10
12
14
16
Day 1
2
4
8
12
16
20
24
28
(4 wk Off Treatment)
Weeks of Rilzabrutinib Treatment
Mean PDAI
Median PDAI

FIG. 11


PDAI Activity Score
CS Usage*, mg/day
Weeks of Rilzabrutinib Treatment
Day 1
(4 wk Off Treatment)
Mean PDAI
Median PDAI
Mean CS
Median CS